Identification of H-2d Restricted T Cell Epitope of Foot-and-mouth Disease Virus Structural Protein VP1 by Liu, Xin-Sheng et al.
RESEARCH Open Access
Identification of H-2d Restricted T Cell Epitope of
Foot-and-mouth Disease Virus Structural Protein
VP1
Xin-Sheng Liu, Yong-Lu Wang
*, Yong-Guang Zhang, Yu-Zhen Fang, Li Pan, Jian-Liang Lu, Peng Zhou,
Zhong-Wang Zhang and Shou-Tian Jiang
Abstract
Background: Foot-and-mouth disease (FMD) is a highly contagious and devastating disease affecting livestock that
causes significant financial losses. Therefore, safer and more effective vaccines are required against Foot-and-mouth
disease virus(FMDV). The purpose of this study is to screen and identify an H-2d restricted T cell epitope from the
virus structural protein VP1, which is present with FMD. We therefore provide a method and basis for studying a
specific FMDV T cell epitope.
Results: A codon-optimized expression method was adopted for effective expression of VP1 protein in colon
bacillus. We used foot-and-mouth disease standard positive serum was used for Western blot detection of its
immunogenicity. The VP1 protein was used for immunizing BALB/c mice, and spleen lymphocytes were isolated.
Then, a common in vitro training stimulus was conducted for potential H-2Dd, H-2Kd and H-2Ld restricted T cell
epitope on VP1 proteins that were predicted and synthesized by using a bioinformatics method. The H-2Kd
restricted T cell epitope pK1 (AYHKGPFTRL) and the H-2Dd restricted T cell epitope pD7 (GFIMDRFVKI) were
identified using lymphocyte proliferation assays and IFN-g ELISPOT experiments.
Conclusions: The results of this study lay foundation for studying the FMDV immune process, vaccine
development, among other things. These results also showed that, to identify viral T cell epitopes, the combined
application of bioinformatics and molecular biology methods is effective.
Background
FMD is an acute, febrile, highly contagious zoonotic dis-
ease [1] that is caused by the FMDV and that mainly
harms cloven-hoofed animals. The pathogen belongs to
the genus FMDV of the small RNA virus branch. Cross-
protection tests and serological tests have confirmed
that FMDV has seven serotypes, namely O, A, C (Eur-
opean type), Asia 1 (Asia 1 type) and the STA1, STA2,
STA3 (South African type) [2]. FMDV antigen has a
complex structure and a wide range of antigenic varia-
tion, but it does not possess cross protection among
reaction types, seven serotypes have a great amount of
antigenic difference, which makes it more difficult for
vaccine prevention [3,4]. Currently, inactivated/
attenuated pathogens or the complete viral antigens are
used as a vaccine. The former has a good effect, but has
biological safety problems; while the effect of the latter
is often very limited. Thus, epitope-based vaccine design
has become the priority and hot spot of current FMD
vaccine research. At present, there are some more suc-
cessful reports about research on the FMD epitope vac-
cine [5-9], but all of these are based on determining B
and T cell epitopes from the FMDV structural and non-
structural proteins. Identification of FMDV epitopes is
also a very active area of research in recent years. Pre-
vious research has identified a number of effective
FMDV epitopes [10-22], which provides important keys
for developing epitope vaccines with higher immuno-
genicity and protective capabilities.
FMDV particles are mainly composed of 4 capsid pro-
teins (i.e., VP1, VP2, VP3 and VP4) with 60 respective
copies. The structural protein VP1 contains major
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easily, which often leads to toxic antigenic strain and
virulence changes. Additionally, it is the main reason for
polymorphic and multi-subtype FMDV [23]. Therefore,
it is particularly important for developing research on
antigen epitopes regarding the FMDV structural protein
VP1.
It is generally believed that anti-infection immunity
against FMDV is mainly related to high levels of antibo-
dies, but with increased research it has become evident
that other parts of the cellular immune response play an
important role in protection against FMD. The produc-
tion of neutralizing antibodies in FMDV infection
requires B cell epitopes and T cell epitopes. The vaccine
cannot elicit a protective im m u n er e s p o n s ew i t h o u tT
cell epitopes [24]. Cytotoxic T lymphocytes (CTL) are
one of the immune cells needed for the body to effec-
tively control viral infection. MHC I molecule restricted
antigen-specific CTL responses are important for viral
clearance, to control viral replication, and to prevent dif-
fusion during viral infection. Previous studies on FMDV
antigen epitopes have mostly concentrated on the study
of B cell epitopes and assistant T cell epitopes. However
there is limited research on FMDV cytotoxic T lympho-
cyte epitopes and its effect on protection against FMDV.
So far, the only discovered cytotoxic T lymphocyte epi-
topes on the FMDV structural protein VP1 are two pig
SLA molecule restricted cytotoxic T lymphocyte epi-
topes [22]. Therefore, an in-depth study on the FMDV
CTL T cell epitopes has important significance to accu-
rately map CTL epitopes in detail for FMDV. This
would illuminate the importance of the cellular immune
response, pathogenesis of the FMDV, and provide
insight in to developing epitope vaccines.
Therefore, the purpose of this study is to identify CTL
T cell epitopes on the FMDV structural protein VP1.
This would provide clues and help for future studies.
We combined bioinformatic predictions and experimen-
tal validation, a method which is widely used and has
successfully identified many antigen epitopes, for the
screening and identification of H-2 restricted T cell epi-
topes on the FMDV structural protein VP1 [25-29].
Additionally, it was used to successfully identify possible
CTL T cell epitopes on two FMDV structural proteins
VP1.
Results
VP1 Antigen Protein Cloning, Expression and
Immunogenicity Analysis
We obtained the complete sequence of the wild-type
FMDV AF/72 strain structural protein VP1 gene
through cloning and sequencing. Sequence analysis
results revealed that the full length VP1 was success-
fully cloned with all 639 nucleotides and 213 amino
acids that encode the protein. The expression of an
exogenous gene in E. coli was controlled by a number
of factors, mainly in the transcription and translation
stages, and it was also important to affect protein
expression using varying passwords. Rare codons in
t h es e q u e n c ew e r ec h a n g e di n t oE .c o l ia d v a n t a g e
codons, thereby optimizing the codons with the wild-
type VP1 gene as reference sequences. Additionally,
the adaptation index of the codons was optimized, and
the GC content was balanced. The synthetic optimiza-
tion sequence was connected with the vector pET28a,
and BL21 (DE3) host bacteria were transformed for
protein expression. Concurrently, we optimized and
confirmed the optimal expression conditions for the
expression of recombinant proteins. The results
showed that the recombinant strain optimally
expressed the protein after being induced with 1 mol/L
I P T Ga t3 7 ° Cf o r3h .A f t e rb eing purified by the affi-
nity layer, VP1 protein was identified by SDS-PAGE
electrophoresis, and the results showed that VP1 pro-
tein was successfully and highly expressed in E. coli
with a molecular weight of approximately 33 kDa,
which was consistent with the expected size (Figure 1).
Western blot analysis results showed that the VP1 pro-
tein generated under conditions promoting optimal
expression can generate a specific reaction with FMDV
type-A standard positive sera, which further confirmed
that the VP1 protein that was generated under
Figure 1 SDS-PAGE Results of VP1 Protein. These results show
that the structural protein VP1 after optimal expression has the size
of 33 kDa, which is consistent with the expected size. 1: Uninduced
control; 2: 3 hour induction; 3: Disintegrating liquid with ultrasonic;
4: Clarifying after disintegrating liquid with ultrasonic and
centrifugation; 5: purifying sample solution with Ni Column,
dissolved inclusion bodies; 6: Purifying flowing liquid with Ni
Column; 7: Purifying Ni-Denature-8.0 wash solution with Ni Column;
8: Purifying Ni-Denature-6.0 wash solution with Ni Column; 9:
Purifying Ni-Denature-4.0 equate with Ni Column;
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expressed in E. coli and that it has acceptable immu-
nogenicity (Figure 2).
CD8
+ T Cell Epitope Prediction Results and Selection
CTL epitope prediction refers to peptides that can be
predicted by looking for the rule of combining antigen
peptide with specific MHC molecules. BIMAS algorithm
experimentally measured peptide-MHC complexes and
established the grade affinity matrix with the dissocia-
tion half-life under pH 6.5 in a 37°C environment, thus
predicting MHC restricted epitopes that have been suc-
cessfully applied to the identification of a wide range of
CTL epitopes [30]. This study utilizes the software to
predict the H-2d restricted cytotoxic T cell epitopes of
FMDV AF/72 strain structural protein VP1. A total of
30 H-2Dd, H-2Kd and H-2Ld restricted T cell epitopes
were identified by the highest score and from those 10
peptides were selected as the candidates (Table 1).
Lymphocyte In Vitro Proliferation Experiment for
Identifying CD8
+ T Cell Epitopes
The MTS colorimetric method was used to verify CD8
+
T lymphocyte proliferation after mouse splenic lympho-
cytes were stimulated with a candidate epitope peptide
section. Significant lymphocyte proliferation occurred in
the positive control group, but no lymphocyte prolifera-
tion was detected in the negative control group. In the
experimental group, the H-2Kd restricted T cell epitope
candidate peptide pK1 and the H-2Dd restricted T cell
epitope candidate peptide section pD7 stimulated the
proliferation of mouse lymphocytes (SI> 2). Additionally,
Figure 2 VP1 Protein Western blot analysis; The results show
that specific bands were available at a molecular weight of 33
kDa. The expression protein and FMDV positive serum generate
strong specific reactions, thereby indicating that VP1 protein with
optimal expression has good immunogenicity and the antigenicity
is not changed
Table 1 Amino acid sequence of the predicted VP1
protein CD8
+ T cell epitopes and BIMAS scores
MHC-
restriction
Code Start
Position
Subsequence Residue
Listing
Score
H-2Ld pL1 103 NPTAYHKGPF 300
pL2 117 LPYTAPHRVL 150
pL3 89 VPNGAPETAL 150
pL4 9 DPVTTTVENY 72
pL5 121 APHRVLATVY 60
pL6 110 GPFTRLALPY 60
pL7 45 QSPTHVIDLM 37.5
pL8 42 IPSQSPTHVI 30
pL9 158 LPASFNFGAI 30
pL10 188 RPLLAVKVTS 30
H-2Dd pD1 138 TGNAGRRGDL 30
pD2 109 KGPFTRLALP 24
pD3 141 AGRRGDLGS 3
pD4 62 VGALLRAATY 10
pD5 45 QSPTHVIDLM 7.2
pD6 41 KIPSQSPTHV 7.2
pD7 33 GFIMDRFVKI 6
pD8 116 ALPYTAPHRV 6
pD9 56 THQHGLVGAL 3
pD10 197 SQDRHKQRII 20
H-2Kd pK1 106 AYHKGPFTRL 3456
pK2 33 FIMDRFVKI 1920
pK3 163 NFGAIRATVI 1152
pK4 71 YYFSDLEIVV 720
pK5 70 TYYFSDLEIV 600
pK6 184 LYCPTPLLAV 600
pK7 204 RIIAPAKQLL 115.2
pK8 52 DLMQTHQHGL 80
pK9 77 EIVVRHDDNL 80
pK10 175 LLVRVKRAEL 80
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could be shown, while the other candidate epitope pep-
tide sections cannot effectively stimulate the prolifera-
tion of mouse lymphocytes sensitized by VP1 protein. In
addition, these peptides were unable to stimulate the
lymphocyte proliferation of PBS immunized mice (SI
<2), (Figure 3). These results suggest that peptide sec-
tion pK1 (AYHKGPFTRL) and pD7 (TGESADPVTT)
may be epitopes of VP1’s protein-specific CTL.
INF-g ELISPOT Experiments Further Confirmed the Results
of the Proliferation Experiments
IFN-g secretion by cells was checked using ELISPOT,
which further validated the results of the T cell prolif-
eration assays. The test results show that mouse spleen
lymphocyte holes stimulated by H-2Kd restricted T cell
epitope pK1 (AYHKGPFTRL) and H-2Dd restricted T
cell epitope pD7 (TGESADPVTT) can be seen as lym-
phocyte colonies within increasing IFN-g secretion.
Mouse splenic lymphocytes stimulated by other peptide
sections and non-stimulated mouse splenic lymphocytes
were used for detecting individual lymphocyte colony
IFN-g secretion or for detecting lymphocyte colonies
that did not secrete IFN-g (Figures 4 and 5). Anova
showed that there were significant differences (P<0.01)
between the spot count from mouse splenic lympho-
cytes that were stimulated by peptide sections pK1 and
pD7 compared with lymphocytes stimulated with other
peptide sections. These results confirmed the observa-
tions in the T cell proliferation experiments and further
confirmed that peptide sections pK1 and pD7 may be
VP1 protein-specific CTL epitopes.
Discussion
Viral antigens are cleaved into oligopeptides of small
molecules, which bind MHC-I molecules forming “anti-
gen-MHC-I complexes”. These complexes present viral
proteins on the surface of antigen-presenting cells
allowing CD8
+ T cells to specifically recognize the viral
protein through their expression of the viral specific
TCR. These viral peptides that are presented on MHC I
to CD8
+ T cells represent CTL epitopes that can initiate
an anti-viral response [30]. Identification of CTL epi-
topes has been a focus of immunology because it is the
key for the research and development of immunodiag-
nostics, immunotherapy and new vaccines. Additionally,
it is helpful for exploring and clarifying the pathogenesis
of microorganisms and the subsequent immune
response [31-33]. CTL play a critical role in the anti-
viral response to infection in the body. However, pre-
vious studies investigating the immune response against
FMD have provided little understanding of the protec-
tive role of cell cytotoxic lymphocytes against the
FMDV. The research on epitopes of the FMDV has
mainly focused on the study of B cell epitopes, which
are associated with humoral immunity, as well as Th
cell epitopes that promote the generation of high-level
protective antibodies. These studies have overlooked the
importance of CTL epitopes as shown with only one
study on CTL epitopes of FMDV [22]. The only
research report of FMDV CTL epitopes predicts possible
CTL epitopes, but does not have in vitro tests to accu-
rately verify these CTL epitopes as immunogenic.
Figure 3 Stimulation index (SI). The measured proliferative
response of splenic cells from mice immunized by VP1 protein.
Stimulation index is the ratio of the value between the stimulated
and control cultures.
Figure 4 IFN-g ELISPOT. The statistical results from the ELISPOT of
immunized Balb/c mice splenic lymphocyte after stimulation with
peptides by Analysis of Variance (ANOVA). The negative control
represents lymphocytes plated with RPMI 1640 without peptides.
The experimental groups are lymphocytes plated with peptides.
Asterisks indicate statistical significance compared with the value of
wells without peptides (P<0.01)
Figure 5 The ELISPOT results of immunized Balb/c splenic
lymphocytes after stimulation with peptides, ConA and two
positive peptides (pk1: H-2K
d restricted, pD7: H-2D
d restricted).
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detailed description of FMDV epitope mapping and has
increased our understanding of the protective effects of
cytotoxic lymphocytes against FMDV.
We identified candidate epitopes using bioinformatics,
and candidate epitopes were scored using an epitope
prediction software. Potential epitopes were determined
based on their scores and the secretion of cytokines
induced by the potential epitopes. As opposed to the
commonly used T cell epitope identification methods,
such as synthetic overlapped peptide screening method,
bioinformatics technology was used to predict and ana-
lyze advantageous antigenic epitopes of the targeted pro-
tein. The epitopes can be pre-determined, thereby
reducing blindness of study. Additionally, the epitopes
can be validated using molecular biology, which
increases the likelihood that the predicted epitopes are
authentic. However, the results of the test suggest that
the software prediction accuracy is low and does not
completely and truly reflect actual epitopes. Therefore,
it should only be used as a reference.
Many viruses have a significantly different function
regarding the frequency of their codon usage compared
to their host cell’s codons. Viral genes may alter the
expression of targeted proteins due to different codon
biases when being expressed in host cells [34-36].
Therefore, we adopted a coded optimization expression
method for the expression of VP1 protein in E. coli and
utilized this method for preparing the FMDV structural
protein VP1 from the mouse immune antigen to prevent
the possibility that the FMDV structural protein VP1
alters the expression of the VP1 protein due to different
codon biases in the E. coli cell expression process.
Otherwise, this could result in changing identified T-cell
epitopes and could limit the accuracy and efficiency of
the expression of VP1. Western blot analysis showed
that the VP1 protein produced under conditions that
promote optimal expression can generate specific reac-
tions with FMDV type-A standard positive sera. Addi-
tionally, we proved that VP1 protein produced under
conditions that promote optimal expression was cor-
rectly expressed in E. coli and maintained immunogeni-
city, ensuring that the T cell epitope amino acid
sequences identified in the following experiments were
correct and effective.
VP1 protein with incomplete Freund’sa d j u v a n tw i t h
the same dose was used to boost the immune response
2 weeks after the primary immunization. Following the
initial boost, we strengthened the immunity once every
two weeks. The immunization method with a total of 3
times of strengthening immunity ensures that mice after
immunization are adequate for inducing and generating
enough long-term memory T cells. This was necessary
to ensure that there were a sufficient number of T
lymphocytes available for in vitro stimulation and to
ensure more accurate test results.
Epitope selection is based on a number of factors,
such as the composition of T cells and the affinity
between the epitope and MHC molecules [37,38]. The
frequency of CD4
+ T cells that secrete IFN-g is
increased with the increase in mononuclear cells. This is
mediated by monocyte-derived cytokine-production
[39,40]. Epitopes can be presented to CD8
+ Tc e l l s
through monocytes. Additionally, CD8
+ T cells also
secrete IFN-g upon activation. In this study, the compo-
sition of the splenic lymphocytes for each mouse was
the same with the constant amount, thus eliminating
errors that may be caused by CD4
+ T cell secretion of
IFN-g. In this study, small peptides composed of ten
amino acids identified through prediction synthesis were
used to carry out in vitro stimulations of splenic lym-
phocytes from immunized mice. The ability of candidate
epitope peptide sections to stimulate and activate mouse
T lymphocytes were evaluated for cell quantity changes
and cell factor secretion, respectively through T cell pro-
liferation assays and IFN-g Elispot experiments. The
results showed that the H-2Kd restricted T cell candi-
date epitope peptide section pK1 (AYHKGPFTRL) and
the H-2Dd restricted T cell candidate peptide epitope
pD7 (TGESADPVTT) can effectively induce activated
chicken T lymphocytes to produce a T cellular response.
Therefore these two candidate peptide epitopes may be
the mouse H-2d restricted cytotoxic T cell epitopes.
The experimental results also indicate that although the
two epitopes have different restrictions, they may pro-
duce T cell responses of the same type. However, this
test currently only validated epitope prediction and the
ability of T lymphocytes to react to the epitope. How-
ever, further tests are required to verify whether these
epitopes are immunogenic. Two CTLs that were identi-
fied by these experiments could not be used because
they were not the natural hosts of FMDV, such as pigs,
cattle, sheep and other cloven-hoofed animals. But the
process and results of these experiments provide initial
evidence for studying the possible development of an
epitope vaccine against FMDV. Additionally, this study
is beneficial in demonstrating the effects of cytotoxic
lymphocytes in protecting against FMD in their
response against the FMDV, which is possible through
the identification of CTL epitopes in mice, and this is a
normal model for the study of FMDV.
FMDV strain AF/72 that was used in these experi-
ments is a vaccine strain that has been used in develop-
ing a FMD vaccine. This strain has demonstrated good
immune effects. The study selected the structural pro-
tein VP1 of strains AF/72 as the protein used to study
epitopes because the structural protein VP1 contains the
major antigenic sites of the foot-and-mouth disease
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Sequence homology analysis of the AF/72 strain struc-
tural protein VP1 showed that, compared with the
FMDV A/NM/XZ/64 (AJ131664) strains, A/NM/EL/60
(AJ131664) strain and GS/LX/62 (AJ131666) strain,
which are isolated in China, showed there was a nucleo-
tide homology of more than 97%. Additionally, the
nucleotide sequences of the zones of the two identified
CTL epitopes did not change. Therefore, the two CTL
epitopes identified in the experiment are representative.
The successful use of biology software for prediction
was considered when targeted epitopes were selected in
the experimental design. Additionally, FMDV molecular
biology characteristics were rarely determined, and the
antigen epitope on the VP1G-H ring that had previously
been identified were not identified in these experiments.
This suggests that the characteristics of this virus’s
molecular biology and previous study results should be
considered on the basis of software prediction in future
epitope analysis tests.
Conclusions
These experiments predicted 30 potential CTL epitopes
on structural protein VP1 through bioinformatics, thus
reducing the scope for the identification of potential epi-
topes and improving the accuracy of the experiments.
Immunological experimental techniques were utilized to
carry out the in vitro identification of the screened can-
didate epitopes that had been predicted. Finally, two
murine H-2d restricted cytotoxic T cell epitopes on the
FMDV VP1 structural protein were identified, including
H-2Kd restricted T cell epitopes pK1 (AYHKGPFTRL)
and H-2Dd restricted T-cell epitope pD7 (TGE-
SADPVTT) from 106 to 115 amino acids and from 4 to
13 amino acids on VP1, respectively. This study pro-
vides direct evidence demonstrating the need for further
clarification of the FMDV T cell epitopes. Additionally,
it establishes research methods for studying other viral
T cell epitopes.
Materials and methods
Virus and mouse
FMDV AF/72 strains were separated, identified and
stored by our laboratory. Female SPF level six-week-old
BALB/c mice were purchased from Lanzhou Institute of
Biological Products and were fed in clean level
environment.
VP1 Antigen Protein Preparation
FMDV virus strain genomic group RNA was taken as a
template. We used a pair of primers (upstream primer:
5’-CACAAATGTACAGGGATGGGT-3’ and down-
stream primer: 5’-GACATGTCCTCCTGCATCT-3’).
Complete nucleotide sequence of VP1 was obtained
through reverse transcription and PCR extension. The
recovered PCR products were connected to pGEM-T
easy vector. The competent cell JM109 was transformed,
and the plasmid was extracted after blue-white screen-
ing; moreover, the clone, which was identified as posi-
tive through PCR and whose enzyme was cut, was sent
to Dalian TaKaRa Biotechnology Co., Ltd for
sequencing.
We followed the E. coli codon bias to reform codons
of wild-type VP1 genes and sent them to Shanghai San-
gon Biotech Co., Ltd for synthesis under the conditions
that there were no changes in the amino acid sequences
of VP1 protein. This ensured that VP1 expression was
accurate and efficient, thereby enabling the mouse
immune program to be of a high level of quality. Synth-
esis genes were connected with vector pET28a and tar-
get protein expression was induced after the BL21
(DE3) host strain was transformed. Affinity chromato-
graphy columns were used for purification. SDS-PAGE
and Western blotting was used for checking the molecu-
lar size and immunogenicity of the VP1 protein after
expression conditions were varied compared with wild-
type VP1 protein.
Epitope Peptide Prediction and Preparation
The BIMAS program http://www-bimas.cit.nih.gov/mol-
bio/hla_bind[44] was used for analyzing and predicting
potential H-2Dd, H- 2Kd and H-2Ld restricted CTL epi-
topes on the VP1 protein according to the VP1 amino
acid sequence. We identified ten H-2Dd, H-2Kd and H-
2Ld restricted T cell epitopes that scored the highest. In
total, 30 peptides were selected and sent to Shanghai
Sangon Biotech Co., Ltd for synthesis. The purity of all
synthetic peptides was higher than 95% based on quanti-
fications from RP-HPLC measurements. The peptides
were reconstituted with a certain amount of DMSO
solution and RPMI1640 at a concentration of 1 mmol/L,
and then the solution was packed and stored at -70°C.
Mice Immunity
After affinity chromatography purification, VP1 protein
was fully mixed with Freund’s complete adjuvant with
e q u a lv o l u m e .S P FB A L B / cm i c ew e r es u b c u t a n e o u s l y
immunized with multi-point abdominal injections with
an initial immunization dose of 100 μg/mouse. Booster
immunizations were carried out 2 weeks later. Incom-
plete Freund’s adjuvant was used during the booster
immunization once every two weeks for an additional
three times. VP1 protein was replaced with PBS for
mice in the control group using the same immunization
procedures. All animal stu d i e sw e r ea p p r o v e db yt h e
Review Board of Lanzhou Veterinary Research Institute,
Chinese Academy of Agricultural Sciences (Permission
number: SYXK-GAN-2004-0005). The mice used in this
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euthanasia was carried out at the end of the experiment
to reduce suffering.
Preparation of Splenic Lymphocytes
After the immunizations were finished, mice were
euthanized and spleens were harvested using sterile
technique, and 3 mL of EZ-Sep ™ Mouse 1× lympho-
cyte isolation was placed in a 35 mm Petri dish with a
200 nylon mesh fixed on the dish. Following harvest, we
made a single cell suspension of the mouse spleen by
gently grinding the spleen using a syringe piston. The
single cell suspension was maintained in 1640 medium
at 0.5 mL. The cell suspension was centrifuged at 800 g
for 30 minutes. The lymphocyte cell layer was isolated,
washed in 10 mL of 1640 medium, and centrifuged at
250 g for 10 minutes. Supernatant was decanted and the
cells were resuspended in serum-free media. Lympho-
cytes were resuspended in 1640 medium at a cell density
of 10
7 cells/mL and were cultured at 37°C in 5% CO2.
T Cell Proliferation Assay
One hundred microliters of the prepared lymphocyte
cell suspension (10
7 cells/mL) was added to each well in
a 96-well plate. Following the plating of the cell suspen-
sion, the synthetic peptide (30 μg/mL) was added with a
final volume of 200 μL/well. Three parallel wells were
made for each peptide section. RPMI 1640 medium was
added in negative control wells without an additional
stimulus. ConA was used for stimulation of the positive
control group. Additionally, three parallel wells were set
up with the final volume of 200 μL/well. The cultures
were incubated at 37°C in a 5% CO2 incubator for 72 h.
We added 20 μl CellTiter 96
® AQueous One Solution
Reagent to each well 4 hours before the end of the cul-
ture. Following the addition of this reagent the cells
were cultured at 37°C in a 5% CO2 incubator. After
incubation, the absorbance was checked at 490 nm. The
mean of the three duplicate wells (x ± s) was calculated,
and the results were expressed as the stimulation index
(SI) (SI = A490 mean of experimental group/A490 mean
of negative control group). A positive result on the sti-
mulation index was considered if SI ≥ 2.
IFN-g ELISPOT Experiment
PBS diluted coating antibody (50 μL) was added to
each well on the PVDF 96-well plate. The plate was
coated overnight at 4°C. The coating liquid was dec-
anted and the plate was washed twice with PBS. The
plate was dried on the sterile absorbent paper follow-
ing the final wash. PBS (1×) diluted blocking solution
was added (200 μL/well) and sealed at 37°C for 1 h.
The blocking solution was decanted. The pre-prepared
suspension of lymphocytes (100 μl at a concentration
of 10
7 cells/100 μl) was added to each well. Synthetic
peptides (10 μl, with a final concentration of 30 μg/
mL) were added to the test group with three parallel
wells prepared for each peptide. ConA (10 μg/mL) was
added to the positive control group, but the negative
control group received no added stimulus. The plate
was covered after all the samples were added. It was
placed in a carbon dioxide incubator and cultured for
24 h at 37°C. The cells and medium in the wells were
decanted after incubation. Ice-cold deionized water
(200 μL/well) was added. The plate was incubated in
an ice bath for 10 min at 4°C. PBST (200 μL) was
added in each well. After being washed five times, we
added diluted biotinylated detection antibody (100 μL)
to each well, which were incubated for 1 h at 37°C.
Labeled detection antibody was incubated and washed.
Then we added diluted HRP-avidin (100 μL) to each
well, which was incubated at 37°C for 1 hour. Chromo-
genic reagent (100 μL) was added to each well after
the above steps and washing. The plate was statically
placed for 30 min at room temperature in a sun-shad-
ing place. After spots grew to a suitable size, the plate
was washed with deionized water 2 times, and then the
development process was stopped. The ELISPOT plate
was placed in the automatic reading meter. The appro-
priate parameters were adjusted, spots were counted,
and various parameters of the spots were recorded for
statistical analysis. The results of the test were ana-
lyzed through variance analysis t tests. The differences
were considered significant if P <0.05, and the differ-
ence was prominent if P <0.01.
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